Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation

Jian An, Shancheng Ren, Stephen J. Murphy, Sumiya Dalangood, Cunjie Chang, Xiaodong Pang, Yangyan Cui, Liguo Wang, Yunqian Pan, Xiaowei Zhang, Yasheng Zhu, Chenji Wang, Geoffrey C. Halling, Liang Cheng, William R. Sukov, R. Jeffrey Karnes, George Vasmatzis, Qing Zhang, Jun Zhang, John C. Cheville & 3 others Jun Yan, Yinghao Sun, Haojie Huang

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

SPOP mutations and TMPRSS2-ERG rearrangements occur collectively in up to 65% of human prostate cancers. Although the two events are mutually exclusive, it is unclear whether they are functionally interrelated. Here, we demonstrate that SPOP, functioning as an E3 ubiquitin ligase substrate-binding protein, promotes ubiquitination and proteasome degradation of wild-type ERG by recognizing a degron motif at the N terminus of ERG. Prostate cancer-associated SPOP mutations abrogate the SPOP-mediated degradation function on the ERG oncoprotein. Conversely, the majority of TMPRSS2-ERG fusions encode N-terminal-truncated ERG proteins that are resistant to the SPOP-mediated degradation because of degron impairment. Our findings reveal degradation resistance as a previously uncharacterized mechanism that contributes to elevation of truncated ERG proteins in prostate cancer. They also suggest that overcoming ERG resistance to SPOP-mediated degradation represents a viable strategy for treatment of prostate cancers expressing either mutated SPOP or truncated ERG. SPOP mutations and TMPRSS2-ERG rearrangements are two of the most prevalent genetic alterations in human prostate cancer. An et al. report that SPOP functions as a tumor suppressor in prostatic cells by promoting ERG degradation, but this function is abrogated by both SPOP mutations and the majority of TMPRSS2-ERG fusions.

Original languageEnglish
Pages (from-to)904-916
Number of pages13
JournalMolecular Cell
Volume59
Issue number6
DOIs
StatePublished - Sep 17 2015

Fingerprint

Oncogene Proteins
Proteasome Endopeptidase Complex
Prostatic Neoplasms
Mutation
Ubiquitin-Protein Ligases
Ubiquitination
Carrier Proteins
Proteins
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

An, J., Ren, S., Murphy, S. J., Dalangood, S., Chang, C., Pang, X., ... Huang, H. (2015). Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Molecular Cell, 59(6), 904-916. https://doi.org/10.1016/j.molcel.2015.07.025

Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. / An, Jian; Ren, Shancheng; Murphy, Stephen J.; Dalangood, Sumiya; Chang, Cunjie; Pang, Xiaodong; Cui, Yangyan; Wang, Liguo; Pan, Yunqian; Zhang, Xiaowei; Zhu, Yasheng; Wang, Chenji; Halling, Geoffrey C.; Cheng, Liang; Sukov, William R.; Karnes, R. Jeffrey; Vasmatzis, George; Zhang, Qing; Zhang, Jun; Cheville, John C.; Yan, Jun; Sun, Yinghao; Huang, Haojie.

In: Molecular Cell, Vol. 59, No. 6, 17.09.2015, p. 904-916.

Research output: Contribution to journalArticle

An, J, Ren, S, Murphy, SJ, Dalangood, S, Chang, C, Pang, X, Cui, Y, Wang, L, Pan, Y, Zhang, X, Zhu, Y, Wang, C, Halling, GC, Cheng, L, Sukov, WR, Karnes, RJ, Vasmatzis, G, Zhang, Q, Zhang, J, Cheville, JC, Yan, J, Sun, Y & Huang, H 2015, 'Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation', Molecular Cell, vol. 59, no. 6, pp. 904-916. https://doi.org/10.1016/j.molcel.2015.07.025
An, Jian ; Ren, Shancheng ; Murphy, Stephen J. ; Dalangood, Sumiya ; Chang, Cunjie ; Pang, Xiaodong ; Cui, Yangyan ; Wang, Liguo ; Pan, Yunqian ; Zhang, Xiaowei ; Zhu, Yasheng ; Wang, Chenji ; Halling, Geoffrey C. ; Cheng, Liang ; Sukov, William R. ; Karnes, R. Jeffrey ; Vasmatzis, George ; Zhang, Qing ; Zhang, Jun ; Cheville, John C. ; Yan, Jun ; Sun, Yinghao ; Huang, Haojie. / Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. In: Molecular Cell. 2015 ; Vol. 59, No. 6. pp. 904-916.
@article{a5e5fd3deb744d2693edd93125488654,
title = "Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation",
abstract = "SPOP mutations and TMPRSS2-ERG rearrangements occur collectively in up to 65{\%} of human prostate cancers. Although the two events are mutually exclusive, it is unclear whether they are functionally interrelated. Here, we demonstrate that SPOP, functioning as an E3 ubiquitin ligase substrate-binding protein, promotes ubiquitination and proteasome degradation of wild-type ERG by recognizing a degron motif at the N terminus of ERG. Prostate cancer-associated SPOP mutations abrogate the SPOP-mediated degradation function on the ERG oncoprotein. Conversely, the majority of TMPRSS2-ERG fusions encode N-terminal-truncated ERG proteins that are resistant to the SPOP-mediated degradation because of degron impairment. Our findings reveal degradation resistance as a previously uncharacterized mechanism that contributes to elevation of truncated ERG proteins in prostate cancer. They also suggest that overcoming ERG resistance to SPOP-mediated degradation represents a viable strategy for treatment of prostate cancers expressing either mutated SPOP or truncated ERG. SPOP mutations and TMPRSS2-ERG rearrangements are two of the most prevalent genetic alterations in human prostate cancer. An et al. report that SPOP functions as a tumor suppressor in prostatic cells by promoting ERG degradation, but this function is abrogated by both SPOP mutations and the majority of TMPRSS2-ERG fusions.",
author = "Jian An and Shancheng Ren and Murphy, {Stephen J.} and Sumiya Dalangood and Cunjie Chang and Xiaodong Pang and Yangyan Cui and Liguo Wang and Yunqian Pan and Xiaowei Zhang and Yasheng Zhu and Chenji Wang and Halling, {Geoffrey C.} and Liang Cheng and Sukov, {William R.} and Karnes, {R. Jeffrey} and George Vasmatzis and Qing Zhang and Jun Zhang and Cheville, {John C.} and Jun Yan and Yinghao Sun and Haojie Huang",
year = "2015",
month = "9",
day = "17",
doi = "10.1016/j.molcel.2015.07.025",
language = "English",
volume = "59",
pages = "904--916",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation

AU - An, Jian

AU - Ren, Shancheng

AU - Murphy, Stephen J.

AU - Dalangood, Sumiya

AU - Chang, Cunjie

AU - Pang, Xiaodong

AU - Cui, Yangyan

AU - Wang, Liguo

AU - Pan, Yunqian

AU - Zhang, Xiaowei

AU - Zhu, Yasheng

AU - Wang, Chenji

AU - Halling, Geoffrey C.

AU - Cheng, Liang

AU - Sukov, William R.

AU - Karnes, R. Jeffrey

AU - Vasmatzis, George

AU - Zhang, Qing

AU - Zhang, Jun

AU - Cheville, John C.

AU - Yan, Jun

AU - Sun, Yinghao

AU - Huang, Haojie

PY - 2015/9/17

Y1 - 2015/9/17

N2 - SPOP mutations and TMPRSS2-ERG rearrangements occur collectively in up to 65% of human prostate cancers. Although the two events are mutually exclusive, it is unclear whether they are functionally interrelated. Here, we demonstrate that SPOP, functioning as an E3 ubiquitin ligase substrate-binding protein, promotes ubiquitination and proteasome degradation of wild-type ERG by recognizing a degron motif at the N terminus of ERG. Prostate cancer-associated SPOP mutations abrogate the SPOP-mediated degradation function on the ERG oncoprotein. Conversely, the majority of TMPRSS2-ERG fusions encode N-terminal-truncated ERG proteins that are resistant to the SPOP-mediated degradation because of degron impairment. Our findings reveal degradation resistance as a previously uncharacterized mechanism that contributes to elevation of truncated ERG proteins in prostate cancer. They also suggest that overcoming ERG resistance to SPOP-mediated degradation represents a viable strategy for treatment of prostate cancers expressing either mutated SPOP or truncated ERG. SPOP mutations and TMPRSS2-ERG rearrangements are two of the most prevalent genetic alterations in human prostate cancer. An et al. report that SPOP functions as a tumor suppressor in prostatic cells by promoting ERG degradation, but this function is abrogated by both SPOP mutations and the majority of TMPRSS2-ERG fusions.

AB - SPOP mutations and TMPRSS2-ERG rearrangements occur collectively in up to 65% of human prostate cancers. Although the two events are mutually exclusive, it is unclear whether they are functionally interrelated. Here, we demonstrate that SPOP, functioning as an E3 ubiquitin ligase substrate-binding protein, promotes ubiquitination and proteasome degradation of wild-type ERG by recognizing a degron motif at the N terminus of ERG. Prostate cancer-associated SPOP mutations abrogate the SPOP-mediated degradation function on the ERG oncoprotein. Conversely, the majority of TMPRSS2-ERG fusions encode N-terminal-truncated ERG proteins that are resistant to the SPOP-mediated degradation because of degron impairment. Our findings reveal degradation resistance as a previously uncharacterized mechanism that contributes to elevation of truncated ERG proteins in prostate cancer. They also suggest that overcoming ERG resistance to SPOP-mediated degradation represents a viable strategy for treatment of prostate cancers expressing either mutated SPOP or truncated ERG. SPOP mutations and TMPRSS2-ERG rearrangements are two of the most prevalent genetic alterations in human prostate cancer. An et al. report that SPOP functions as a tumor suppressor in prostatic cells by promoting ERG degradation, but this function is abrogated by both SPOP mutations and the majority of TMPRSS2-ERG fusions.

UR - http://www.scopus.com/inward/record.url?scp=84941792992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941792992&partnerID=8YFLogxK

U2 - 10.1016/j.molcel.2015.07.025

DO - 10.1016/j.molcel.2015.07.025

M3 - Article

VL - 59

SP - 904

EP - 916

JO - Molecular Cell

JF - Molecular Cell

SN - 1097-2765

IS - 6

ER -